摘要
目的评价聚乙二醇干扰素(Peg-IFN)α-2a治疗HBe Ag阴性慢性乙型肝炎的有效性。方法电子检索Cochrane Library、Medline、Embase、EBSCO、OVID、中国生物医学文献数据库(CBM)、中文科技期刊数据库(VIP)、中国期刊全文数据库(CNKI)、万方数字化期刊全文数据库及手工检索查找Peg-IFNα-2 a与其它抗病毒药物(恩替卡韦、拉米夫定及普通干扰素)治疗HBe Ag阴性慢性乙型肝炎的随机对照研究和临床对照研究。评价纳入的原始研究,采用Rev Man 5.2软件进行Meta分析。结果共纳入5项研究包括180例HBe Ag阴性慢性乙型肝炎患者,Meta分析结果提示Peg-IFNα-2a治疗HBe Ag阴性慢性乙型肝炎的ALT复常率[OR=4.04,95%CI(1.37,11.86),P=0.01]、HBV DNA转阴率[OR=8.28,95%CI(0.95,72.49)]明显优于对照组,差异有统计学意义(P<0.05)。Peg-IFNα-2 a治疗HBe Ag阴性慢性乙型肝炎的HBs Ag转阴率较对照组好[OR=8.28,95%CI(0.95,72.49)],但差异无统计学意义(P=0.06)。结论 Peg-IFNα-2 a治疗HBe Ag阴性的慢性乙型肝炎有较好的疗效且复发率、耐药率低。
Objectives To evaluate the effectiveness and safety of pegylated interferons（ Peg-IFN）α-2 a therapy. Meth-ods Publications randomized controlled studies and clinical control study of Peg-IFNα-2a versus other antiviral drugs for HBeAg negative patients with CHB were searched from PubMed, Embase, the Cochrane Library, Web of science, OVID, CNKI, VIP and CBM（ Chinese Biological Medical Literature） and manual retrieval original research was analysed and evaluated using RevMan 5. 2 software for Meta analysis. Results Five eligible studies（180 patients in total）were included in the analysis. Peg-IFNα-2a thera-py produced efficiency significantly HBV DNA reduction[OR =8.28,95%CI（0.95,72.49）]and ALT [OR =4.04,95%CI （1. 37,11. 86）,P=0. 01] rate than that of other antiviral drugs（P〈0. 05）. Conclusion The Peg-IFNα-2a therapy for HBeAg negative patients with CHB was good effect,and low of reccurent rate and resistant.
出处
《四川医学》
CAS
2015年第10期1385-1388,共4页
Sichuan Medical Journal
